+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5214046
  • Report
  • December 2020
  • Region: Global
  • 200 pages
  • The Business Research Company

FEATURED COMPANIES

  • 3SBio
  • Amgen
  • Biocon
  • Boehringer Ingelheim
  • Celgen Biopharma
  • Coherus BioSciences
Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar monoclonal antibodies market.

This report focuses on biosimilar monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the biosimilar monoclonal antibodies market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the biosimilar monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biosimilar Monoclonal Antibodies market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilar monoclonal antibodies market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The biosimilar monoclonal antibodies market section of the report gives context. It compares the biosimilar monoclonal antibodies market with other segments of the biosimilar monoclonal antibodies market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, biosimilar monoclonal antibodies indicators comparison.
Scope

Markets Covered:

1) By Type: Synthetic Chemicals; Biopharmaceuticals; Others
2) By Application: Chronic & Autoimmune Diseases; Oncology; Others

Companies Mentioned: Pfizer; Novartis; Allergan; Coherus BioSciences; Biocon

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio
  • Amgen
  • Biocon
  • Boehringer Ingelheim
  • Celgen Biopharma
  • Coherus BioSciences
1. Executive Summary

2. Biosimilar Monoclonal Antibodies Market Characteristics

3. Biosimilar Monoclonal Antibodies Market Size And Growth
3.1. Global Biosimilar Monoclonal Antibodies Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Biosimilar Monoclonal Antibodies Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Biosimilar Monoclonal Antibodies Market Segmentation
4.1. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Synthetic Chemicals
  • Biopharmaceuticals
  • Others
4.2. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Chronic & Autoimmune Diseases
  • Oncology
  • Others
5. Biosimilar Monoclonal Antibodies Market Regional And Country Analysis
5.1. Global Biosimilar Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Biosimilar Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Biosimilar Monoclonal Antibodies Market
6.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market Overview
6.2. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Biosimilar Monoclonal Antibodies Market
7.1. China Biosimilar Monoclonal Antibodies Market Overview
7.2. China Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Biosimilar Monoclonal Antibodies Market
8.1. India Biosimilar Monoclonal Antibodies Market Overview
8.2. India Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Biosimilar Monoclonal Antibodies Market
9.1. Japan Biosimilar Monoclonal Antibodies Market Overview
9.2. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Biosimilar Monoclonal Antibodies Market
10.1. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Biosimilar Monoclonal Antibodies Market
11.1. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Biosimilar Monoclonal Antibodies Market
12.1. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Biosimilar Monoclonal Antibodies Market
13.1. Western Europe Biosimilar Monoclonal Antibodies Market Overview
13.2. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Biosimilar Monoclonal Antibodies Market
14.1. UK Biosimilar Monoclonal Antibodies Market Overview
14.2. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Biosimilar Monoclonal Antibodies Market
15.1. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Biosimilar Monoclonal Antibodies Market
16.4. France Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Biosimilar Monoclonal Antibodies Market
17.1. Eastern Europe Biosimilar Monoclonal Antibodies Market Overview
17.2. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Biosimilar Monoclonal Antibodies Market
18.1. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Biosimilar Monoclonal Antibodies Market
19.1. North America Biosimilar Monoclonal Antibodies Market Overview
19.2. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Biosimilar Monoclonal Antibodies Market
20.1. USA Biosimilar Monoclonal Antibodies Market Overview
20.2. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Biosimilar Monoclonal Antibodies Market
21.1. South America Biosimilar Monoclonal Antibodies Market Overview
21.2. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Biosimilar Monoclonal Antibodies Market
22.1. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Biosimilar Monoclonal Antibodies Market
23.1. Middle East Biosimilar Monoclonal Antibodies Market Overview
23.2. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Biosimilar Monoclonal Antibodies Market
24.1. Africa Biosimilar Monoclonal Antibodies Market Overview
24.2. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Biosimilar Monoclonal Antibodies Market Competitive Landscape And Company Profiles
25.1. Biosimilar Monoclonal Antibodies Market Competitive Landscape
25.2. Biosimilar Monoclonal Antibodies Market Company Profiles
25.2.1. Pfizer
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Novartis
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Allergan
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Coherus BioSciences
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Biocon
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Biosimilar Monoclonal Antibodies Market

27. Biosimilar Monoclonal Antibodies Market Trends And Strategies

28. Biosimilar Monoclonal Antibodies Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio
  • Amgen
  • Biocon
  • Boehringer Ingelheim
  • Celgen Biopharma
  • Coherus BioSciences
Major players in the biosimilar monoclonal antibodies market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, and Intas Pharmaceuticals Limited.

The global biosimilar monoclonal antibodies market is expected to decline from $3.21 billion in 2019 to $3.04 billion in 2020 at a compound annual growth rate (CAGR) of -5.18%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $7.18 billion in 2023 at a CAGR of 33.13%.

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products.

In May 2020, AbbVie, a US-based biopharmaceutical company, has acquired Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies. Allergan is an Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, eye care, and others.

The biosimilar monoclonal antibodies market covered in this report is segmented by type into synthetic chemicals; biopharmaceuticals; others and by application into chronic & autoimmune diseases; oncology; others.

Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the biosimilar monoclonal antibodies market. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars including 4 originating biologics could enter the US commercial market. The strict government policies for approval of these drugs negatively impact manufacturers in the biosimilar monoclonal antibodies market.

The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American cancer society (ACS), in 2020, about 1.8 million new cancer cases are expected in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market.

The focus areas for many companies in the biosimilar monoclonal antibodies market has shifted to mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities, or to gain access to new markets. In February 2017, Aurobindo Pharma Limited announced that it had acquired four cell culture-derived biosimilar products from TL Biopharmaceutical AG of Switzerland. As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another instance, in May 2020, AbbVie, a US-based biopharmaceutical company, announced its decision to acquire Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie's revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies.
Note: Product cover images may vary from those shown
  • Pfizer
  • Novartis
  • Allergan
  • Coherus BioSciences
  • Biocon
  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • BioXpress Therapeutics
  • Intas Pharmaceuticals Limited
  • Genor BioPharma Co. Ltd
  • BIOCAD
  • Dr. Reddys Laboratories Ltd
  • 3SBio
  • Reliance Life Sciences
  • Hisun Pharma
  • Celgen Biopharma
  • Torrent Pharmaceuticals
  • Cadila Healthcare
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll